A Lung Adenocarcinoma Patient With a Rare EGFR E709_T710delinsD Mutation Showed a Good Response to Afatinib Treatment: A Case Report and Literature Review

A Lung Adenocarcinoma Patient With a Rare EGFR E709_T710delinsD Mutation Showed a Good Response to Afatinib Treatment: A Case Report and Literature Review

For advanced lung adenocarcinoma patients with common epidermal growth factor receptor (EGFR) mutations (exon 19 deletions or the exon 21 L858R mutation), tyrosine kinase inhibitors (TKIs) are the standard therapies, and achieve favorable responses. However, for the rare EGFR deletion-insertion muta...

Full description

Bibliographic Details
Main Authors: Yu Wei, Yueli Cui, Yao Guo, Lei Li, Liang Zeng
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Oncology
Subjects:
NSCLC
EGFR mutation
exon 18
E709_T710insdelD
afatinib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.700345/full

Similar Items

Similar Items